The Scientist

» geron

Most Recent

image: Geron hESC Trial to Resume?

Geron hESC Trial to Resume?

By | May 27, 2014

Nearly three years after Geron shuttered its stem cell program, BioTime receives funding to relaunch a Phase 1 trial for spinal cord injury.

0 Comments

image: Geron’s Stem Cell Program Sold

Geron’s Stem Cell Program Sold

By | October 2, 2013

The company, which launched the first ever clinical trial for a human embryonic stem cell therapy before shuttering its stem cell arm, has finally struck a deal with BioTime.

0 Comments

image: Geron Sells Stem Cell Assets

Geron Sells Stem Cell Assets

By | January 8, 2013

BioTime finalizes a deal to buy Geron’s defunct human embryonic stem cell assets.

0 Comments

image: BioTime Seeks Geron Stem Cell Assets

BioTime Seeks Geron Stem Cell Assets

By | November 13, 2012

Two former Geron CEOs make a bid for the company’s defunct human embryonic stem cell business.

1 Comment

image: First hESC Trial Kaput

First hESC Trial Kaput

By | November 15, 2011

Geron is terminating a clinical trial testing a human embryonic stem cell treatment for spinal cord injury.

30 Comments

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham